Diagnosis and therapy of multiple myeloma
The Korean Journal of Internal Medicine
; : 263-273, 2013.
Article
in En
| WPRIM
| ID: wpr-35113
Responsible library:
WPRO
ABSTRACT
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel agents including thalidomide, lenalidomide, and bortezomib. The first step is recognizing the symptoms and starting prompt treatment. Different strategies should be selected for young and elderly subjects. Young patients are commonly eligible for transplantation, which is now considered the standard approach for this setting, and various inductions therapies containing novel agents are available before transplantation. Elderly patients are usually not eligible for transplantation, and gentler approaches with new drugs combinations are used for their treatment.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Prognosis
/
Pyrazines
/
Thalidomide
/
Boronic Acids
/
Age Factors
/
Stem Cell Transplantation
/
Immunologic Factors
/
Multiple Myeloma
/
Antineoplastic Agents
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
The Korean Journal of Internal Medicine
Year:
2013
Type:
Article